Loading…
Compass Therapeutics, Inc. is projected to rise to $2.74 by 2027, a +43% move from its current price of $1.91. CMPX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.86 | $1.91 | $1.96 | +0.02% |
| Aug 4 | $1.84 | $1.91 | $1.98 | +0.04% |
| Aug 5 | $1.83 | $1.91 | $2.00 | +0.05% |
| Aug 6 | $1.82 | $1.91 | $2.01 | +0.07% |
| Aug 7 | $1.81 | $1.91 | $2.02 | +0.09% |
| Aug 8 | $1.80 | $1.91 | $2.03 | +0.11% |
| Aug 9 | $1.79 | $1.91 | $2.04 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.79 | $1.91 | $2.04 | +0.12% |
| Week 2 | $1.74 | $1.91 | $2.10 | +0.25% |
| Week 3 | $1.71 | $1.92 | $2.15 | +0.37% |
| Week 4 | $1.68 | $1.92 | $2.19 | +0.49% |
| Week 5 | $1.66 | $1.92 | $2.23 | +0.62% |
| Week 6 | $1.64 | $1.92 | $2.26 | +0.74% |
| Week 7 | $1.62 | $1.93 | $2.29 | +0.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company that develops antibody-based therapeutics for the treatment of various human diseases in the United States. Its lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEGF-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
CMPX is currently trading at $1.94 with a market capitalization of $349.37M and a rank of 3343. The stock sits in the Healthcare sector as a clinical-stage biopharmaceutical company focused on antibody-based therapies. The near-term price picture is neutral in 2026, but the forecast shows a bullish trajectory starting in 2027, with average prices rising through the decade and beyond.
By 2030, the forecasted average is $4.15, and by 2050 the average is $22.78, suggesting substantial long-term upside within a high-variance equity profile.
A major floor 15.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 22.5% above — a clean break opens room to run.
A major ceiling 241.9% above — clearing it would confirm fresh momentum.
Key CMPX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CMPX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.98 | Sell | $1.97 | Sell |
| MA 10 | $2.03 | Sell | $2.02 | Sell |
| MA 20 | $2.13 | Sell | $2.07 | Sell |
| MA 50 | $2.11 | Sell | $2.32 | Sell |
| MA 100 | $3.15 | Sell | $2.93 | Sell |
| MA 200 | $4.22 | Sell | $3.42 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.16 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -127.91 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -10.75 | Sell |
| Bollinger %B (20,2) | 0.09 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | -0.13 | Sell |
| Ultimate (7,14,28) | 29.67 | Buy |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 1.91 | Sell |
| ADX (14) | 17.15 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is NEUTRAL with an RSI of 40. The moving averages show SMA50 at $2.11 and SMA200 at $4.24, while the stock currently finds support at $1.94 and faces resistance near $2.34. The 30-day price range spans from $1.63 to $2.31, indicating limited near-term downside but notable upside potential should momentum pick up.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.67 | $1.91 | $2.52 | 0% | Neutral | |
| $2.20 | $2.74 | $3.59 | +43% | Bullish | |
| $2.65 | $3.38 | $4.59 | +77% | Bullish | |
| $2.91 | $3.80 | $5.29 | +99% | Bullish | |
| $3.16 | $4.19 | $5.98 | +120% | Bullish | |
| $3.24 | $4.38 | $6.37 | +129% | Bullish | |
| $3.81 | $5.23 | $7.74 | +174% | Bullish | |
| $4.62 | $6.43 | $9.68 | +237% | Bullish | |
| $5.00 | $7.05 | $10.78 | +269% | Bullish | |
| $5.72 | $8.18 | $12.67 | +328% | Bullish | |
| $8.69 | $13.19 | $21.66 | +591% | Bullish | |
| $14.35 | $24.11 | $43.09 | +11.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.67 | $1.91 | $2.35 | +0.00% |
| September 2026 | $1.69 | $1.99 | $2.41 | +4.33% |
| October 2026 | $1.63 | $1.94 | $2.37 | -2.60% |
| November 2026 | $1.63 | $1.94 | $2.40 | +0.12% |
| December 2026 | $1.69 | $2.03 | $2.52 | +4.26% |
Click any year to see its month-by-month CMPX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CMPX to range from $1.67 to $2.52 through 2026. The $1.91 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The CMPX price prediction for 2027 points to an average of $2.74 (low $2.20, high $3.59) — a potential gain of +43% on today's $1.91. Momentum favours further upside here.
In 2028, CMPX is projected to trade between $2.65 and $4.59, averaging $3.38 — a potential gain of +77% from today's $1.91. That is up +24% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Compass Therapeutics, Inc.'s 2029 outlook centres on $3.80, within a $2.91 to $5.29 range. That is up +12% on the projected 2028 average. That marks a +99% change versus current levels. Momentum favours further upside here.
By 2030, CMPX could reach as high as $5.98, with a base case around $4.19 and support toward $3.16 — roughly +120% from $1.91. Buyers look set to stay in control over this stretch.
Expect CMPX to range from $3.24 to $6.37 through 2031. The $4.38 average target implies a +129% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The CMPX price prediction for 2032 points to an average of $5.23 (low $3.81, high $7.74) — a potential gain of +174% on today's $1.91. Buyers look set to stay in control over this stretch.
In 2033, CMPX is projected to trade between $4.62 and $9.68, averaging $6.43 — a potential gain of +237% from today's $1.91. That is up +23% on the projected 2032 average. Momentum favours further upside here.
Compass Therapeutics, Inc.'s 2034 outlook centres on $7.05, within a $5.00 to $10.78 range. That is up +10% on the projected 2033 average. That marks a +269% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, CMPX could reach as high as $12.67, with a base case around $8.18 and support toward $5.72 — roughly +328% from $1.91. Momentum favours further upside here.
Expect CMPX to range from $8.69 to $21.66 through 2040. The $13.19 average target implies a +591% move from current prices. That is up +61% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The CMPX price prediction for 2050 points to an average of $24.11 (low $14.35, high $43.09) — a potential gain of +11.6x on today's $1.91. Momentum favours further upside here.
Investing $1,000 in CMPX today (≈ 523.560209 CMPX) could be worth
$12,621.56
+$11,621.56 (+1162%) by 2050 · US Dollar
Based on the average projected CMPX price of $24.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CMPXwould be worth at today's price.
$1,000 invested in CMPX on Jul 31, 2025 (≈ 336.700333 CMPX) would be worth
$643.1
-$356.9 (-35.7%) today · 0.64× · US Dollar
Based on a CMPX entry price of $2.97 vs. today's $1.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.07 | $922.71 | -7.7% |
| 1 month ago | $2.18 | $876.15 | -12.4% |
| 3 months ago | $1.96 | $974.49 | -2.6% |
| 6 months ago | $6.52 | $292.94 | -70.7% |
| 1 year ago | $2.97 | $643.1 | -35.7% |
| All time (5.0y) ago | $4.79 | $398.75 | -60.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CMPX forecast.
Our base-case forecast reaches $3.80 around 2030.
Implied market cap at $3.80: $684.33M
The multi-year forecast shows a bullish trajectory beginning in 2027 and extending through 2050. The 2026 forecast yields an average price of $1.94 with neutral sentiment and a 0.0 ROI. From 2027 onward, the averages rise to $2.76 in 2027, $3.42 in 2028, $3.80 in 2029, and $4.15 in 2030, with progressively higher levels thereafter.
By 2031 the average is $4.32, by 2032 $5.12, by 2033 $6.27, by 2034 $6.90, and by 2035 $7.99. The forecast continues higher to $12.73 by 2040 and $22.78 by 2050, with ROIs of 42.2, 76.1, 95.7, 113.9, 122.5, 164, 223.4, 255.6, 311.8, 556, and 1074.2 respectively, all labeled as BULLISH except 2026 which is NEUTRAL. These figures imply meaningful upside over the long run but remain estimates, not guarantees, and depend on future market and company-specific developments.
Tap a question to reveal the answer.
The 2026 forecast shows min $1.67, avg $1.94, max $2.56 with ROI 0 and sentiment NEUTRAL.
The 2030 forecast shows min $3.10, avg $4.15, max $5.98 with ROI 113.9 and sentiment BULLISH.
The outlook from 2027 onward is BULLISH, with averages rising from $2.76 in 2027 to $22.78 by 2050 and ROIs advancing from 42.2 to 1074.2. These are estimates, not guarantees.
Current price is $1.94 and market cap is $349.37M.
2040 forecast: min $8.25, avg $12.73, max $21.22 with ROI 556 and sentiment BULLISH. 2050 forecast: min $13.23, avg $22.78, max $41.47 with ROI 1074.2 and sentiment BULLISH.
Compass Therapeutics, Inc. Community Discussion
0Share your Compass Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.